{"entity":{"id":"idea-senolytics-after-chemo","kind":"idea","name":"One-two punch: clear senescent cells after chemotherapy","aka":[],"tldr":"Chemotherapy leaves behind senescent cells that inflame tissues and help tumours relapse. A short course of senolytic drugs afterwards might reduce relapse and long-term side effects at once.","summary":"This idea proposes a one-two punch: chemotherapy leaves senescent cells that inflame tissues and help tumours relapse, so a short senolytic course afterwards might cut relapse and late side effects at once. Therapy-induced senescence promotes relapse, cachexia and frailty in models, and senolytics (navitoclax, BCL-XL PROTACs, dasatinib plus quercetin) and uPAR CAR-T clear such cells preclinically (Cellular senescence pathway). The hypothesis is that senolytic consolidation reduces relapse and frailty in patients with a high senescence burden measured by p16, and platelet-sparing BCL-XL degraders remove the toxicity barrier. The test is a randomised phase 2 of such a degrader against placebo after adjuvant chemotherapy in Triple-negative breast cancer (TNBC) or Ovarian cancer.","asOf":"2026-09-08","links":[{"label":"Demaria et al., Cellular senescence promotes adverse effects of chemotherapy and cancer relapse (Cancer Discovery 2017)","url":"https://doi.org/10.1158/2159-8290.CD-16-0241"}],"tags":["mechanism","open-question"],"related":[],"cancers":["tnbc","ovarian"],"sections":["rejuvenation"],"technologies":["protac-degrader","geriatric-assessment"],"targets":["bcl2"],"drugs":[],"companies":[],"institutions":["mskcc","mayo-clinic"],"pathways":["senescence","apoptosis-bcl2"],"terms":["senescent-cells"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-demaria-cancer-discov"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Senolytic consolidation after chemotherapy reduces relapse and treatment-related frailty in patients with high post-treatment senescence burden (p16 expression in blood cells or tumour).","rationale":"Lowe, Demaria, and Kirkland preclinical data; p16INK4a in T cells is a validated senescence biomarker; platelet-sparing BCL-XL degraders remove the main toxicity barrier.","test":"Randomised phase 2 of a platelet-sparing BCL-XL degrader vs placebo after adjuvant chemotherapy in TNBC or ovarian cancer, endpoints DFS and geriatric-assessment frailty scores.","maturity":"preclinical-evidence"},"route":"/ideas/idea-senolytics-after-chemo/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"}],"technology":[{"id":"geriatric-assessment","kind":"technology","name":"Geriatric assessment","route":"/technologies/geriatric-assessment/"},{"id":"protac-degrader","kind":"technology","name":"PROTACs & molecular glues (targeted protein degradation)","route":"/technologies/protac-degrader/"},{"id":"rejuv-frontier-senolytics","kind":"technology","name":"Senolytics after cancer treatment","route":"/technologies/rejuv-frontier-senolytics/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"}],"institution":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"pathway":[{"id":"senescence","kind":"pathway","name":"Cellular senescence","route":"/pathways/senescence/"},{"id":"apoptosis-bcl2","kind":"pathway","name":"Intrinsic apoptosis (BCL-2 family)","route":"/pathways/apoptosis-bcl2/"}],"term":[{"id":"senescent-cells","kind":"term","name":"Hallmark (2022): senescent cells","route":"/terms/senescent-cells/"}],"paper":[{"id":"paper-demaria-cancer-discov","kind":"paper","name":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","route":"/key-papers/paper-demaria-cancer-discov/"}]}}